- Home
- CHRS vs SMHI Comparison
CHRS vs SMHI Comparison
Compare CHRS & SMHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- SMHI
- Stock Information
- Founded
- CHRS 2010
- SMHI 1989
- Country
- CHRS United States
- SMHI United States
- Employees
- CHRS N/A
- SMHI N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- SMHI Marine Transportation
- Sector
- CHRS Health Care
- SMHI Consumer Discretionary
- Exchange
- CHRS Nasdaq
- SMHI Nasdaq
- Market Cap
- CHRS 191.3M
- SMHI 189.9M
- IPO Year
- CHRS 2014
- SMHI N/A
- Fundamental
- Price
- CHRS $1.24
- SMHI $6.76
- Analyst Decision
- CHRS Strong Buy
- SMHI
- Analyst Count
- CHRS 4
- SMHI 0
- Target Price
- CHRS $5.38
- SMHI N/A
- AVG Volume (30 Days)
- CHRS 2.0M
- SMHI 151.1K
- Earning Date
- CHRS 03-12-2025
- SMHI 02-27-2025
- Dividend Yield
- CHRS N/A
- SMHI N/A
- EPS Growth
- CHRS N/A
- SMHI N/A
- EPS
- CHRS N/A
- SMHI N/A
- Revenue
- CHRS $304,340,000.00
- SMHI $274,636,000.00
- Revenue This Year
- CHRS $2.47
- SMHI $6.04
- Revenue Next Year
- CHRS N/A
- SMHI $11.18
- P/E Ratio
- CHRS N/A
- SMHI N/A
- Revenue Growth
- CHRS 44.19
- SMHI 3.89
- 52 Week Low
- CHRS $0.66
- SMHI $5.80
- 52 Week High
- CHRS $2.87
- SMHI $15.36
- Technical
- Relative Strength Index (RSI)
- CHRS 37.51
- SMHI 50.31
- Support Level
- CHRS $1.38
- SMHI $6.57
- Resistance Level
- CHRS $1.45
- SMHI $7.28
- Average True Range (ATR)
- CHRS 0.13
- SMHI 0.33
- MACD
- CHRS -0.04
- SMHI 0.01
- Stochastic Oscillator
- CHRS 4.50
- SMHI 23.75
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.
About SMHI SEACOR Marine Holdings Inc.
Seacor Marine Holdings Inc provides world-wide marine and support transportation services to offshore energy facilities globally. The company operates and manages a diverse fleet of offshore support vessels that deliver cargo and personnel to offshore installations including wind farms; handle anchors and mooring equipment for offshore rigs and platforms. Its geographical segment includes the United States (Gulf of Mexico); Africa and Europe; Middle East and Asia and Latin America.